The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

At a pro-Israel conference in Washington DC, former US President Donald Trump criticised American Jewish voters supporting Kamala Harris. He warned of existential threats to Israel if Harris wins ...

TIME's senior sports correspondent Sean Gregory tries his hand at several Olympic sports while learning from Olympians. Subscribe now to get unlimited access to TIME.com and more! Tidal action ...

A shortlist of the biggest headlines, recommended stories, and a special collection of news items that you should check out.

Estranged couple blame each other for a gun battle at Russia’s most successful online retailer that killed two and wounded seven ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...